177 related articles for article (PubMed ID: 11145893)
21. Involvement of multiple epitope-specific cytotoxic T-lymphocyte responses in vaccine-based control of simian immunodeficiency virus replication in rhesus macaques.
Kawada M; Igarashi H; Takeda A; Tsukamoto T; Yamamoto H; Dohki S; Takiguchi M; Matano T
J Virol; 2006 Feb; 80(4):1949-58. PubMed ID: 16439550
[TBL] [Abstract][Full Text] [Related]
22. Initiation of antiretroviral therapy during chronic SIV infection leads to rapid reduction in viral loads and the level of T-cell immune response.
Boyer JD; Kumar S; Robinson T; Parkinson R; Wu L; Lewis M; Weiner DB
J Med Primatol; 2006 Aug; 35(4-5):202-9. PubMed ID: 16872283
[TBL] [Abstract][Full Text] [Related]
23. Adoptive transfer of simian immunodeficiency virus (SIV) naïve autologous CD4(+) cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status.
Villinger F; Brice GT; Mayne AE; Bostik P; Mori K; June CH; Ansari AA
Blood; 2002 Jan; 99(2):590-9. PubMed ID: 11781243
[TBL] [Abstract][Full Text] [Related]
24. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy.
Horiike M; Iwami S; Kodama M; Sato A; Watanabe Y; Yasui M; Ishida Y; Kobayashi T; Miura T; Igarashi T
Virology; 2012 Feb; 423(2):107-18. PubMed ID: 22196013
[TBL] [Abstract][Full Text] [Related]
25. Transient early post-inoculation anti-retroviral treatment facilitates controlled infection with sparing of CD4+ T cells in gut-associated lymphoid tissues in SIVmac239-infected rhesus macaques, but not resistance to rechallenge.
Lifson JD; Piatak M; Cline AN; Rossio JL; Purcell J; Pandrea I; Bischofberger N; Blanchard J; Veazey RS
J Med Primatol; 2003 Aug; 32(4-5):201-10. PubMed ID: 14498980
[TBL] [Abstract][Full Text] [Related]
26. Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques.
Silvera P; Racz P; Racz K; Bischofberger N; Crabbs C; Yalley-Ogunro J; Greenhouse J; Jiang JB; Lewis MG
AIDS Res Hum Retroviruses; 2000 May; 16(8):791-800. PubMed ID: 10826485
[TBL] [Abstract][Full Text] [Related]
27. T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infection.
Richardson MW; Sverstiuk AE; Silvera P; Greenhouse J; Lisziewicz J; Lori F; Khalili K; Lewis MG; Rappaport J
DNA Cell Biol; 2004 Jan; 23(1):1-13. PubMed ID: 14965468
[TBL] [Abstract][Full Text] [Related]
28. Cytotoxic T lymphocyte responses to human immunodeficiency virus: control and escape.
Sewell AK; Price DA; Oxenius A; Kelleher AD; Phillips RE
Stem Cells; 2000; 18(4):230-44. PubMed ID: 10924089
[TBL] [Abstract][Full Text] [Related]
29. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques.
Van Rompay KK; Cherrington JM; Marthas ML; Berardi CJ; Mulato AS; Spinner A; Tarara RP; Canfield DR; Telm S; Bischofberger N; Pedersen NC
Antimicrob Agents Chemother; 1996 Nov; 40(11):2586-91. PubMed ID: 8913470
[TBL] [Abstract][Full Text] [Related]
30. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy.
Shen A; Zink MC; Mankowski JL; Chadwick K; Margolick JB; Carruth LM; Li M; Clements JE; Siliciano RF
J Virol; 2003 Apr; 77(8):4938-49. PubMed ID: 12663799
[TBL] [Abstract][Full Text] [Related]
31. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment.
Lifson JD; Rossio JL; Piatak M; Parks T; Li L; Kiser R; Coalter V; Fisher B; Flynn BM; Czajak S; Hirsch VM; Reimann KA; Schmitz JE; Ghrayeb J; Bischofberger N; Nowak MA; Desrosiers RC; Wodarz D
J Virol; 2001 Nov; 75(21):10187-99. PubMed ID: 11581387
[TBL] [Abstract][Full Text] [Related]
32. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses.
Markowitz M; Vesanen M; Tenner-Racz K; Cao Y; Binley JM; Talal A; Hurley A; Jin X; Chaudhry MR; Yaman M; Frankel S; Heath-Chiozzi M; Leonard JM; Moore JP; Racz P; Nixon DF; Ho DD
J Infect Dis; 1999 Mar; 179(3):527-37. PubMed ID: 9952358
[TBL] [Abstract][Full Text] [Related]
33. Neutralizing antibodies administered before, but not after, virulent SHIV prevent infection in macaques.
Foresman L; Jia F; Li Z; Wang C; Stephens EB; Sahni M; Narayan O; Joag SV
AIDS Res Hum Retroviruses; 1998 Aug; 14(12):1035-43. PubMed ID: 9718118
[TBL] [Abstract][Full Text] [Related]
34. An anti-HIV strategy combining chemotherapy and therapeutic vaccination.
Rosenwirth B; Bogers WM; Nieuwenhuis IG; Haaft PT; Niphuis H; Kuhn EM; Bischofberger N; Erfle V; Sutter G; Berglund P; Liljestrom P; Uberla K; Heeney JL
J Med Primatol; 1999; 28(4-5):195-205. PubMed ID: 10593486
[TBL] [Abstract][Full Text] [Related]
35. Characterization of the pathogenic KU-SHIV model of acquired immunodeficiency syndrome in macaques.
Joag SV; Li Z; Foresman L; Pinson DM; Raghavan R; Zhuge W; Adany I; Wang C; Jia F; Sheffer D; Ranchalis J; Watson A; Narayan O
AIDS Res Hum Retroviruses; 1997 May; 13(8):635-45. PubMed ID: 9168232
[TBL] [Abstract][Full Text] [Related]
36. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection.
Van Rompay KK; Berardi CJ; Aguirre NL; Bischofberger N; Lietman PS; Pedersen NC; Marthas ML
AIDS; 1998 Jun; 12(9):F79-83. PubMed ID: 9662190
[TBL] [Abstract][Full Text] [Related]
37. Early antibody therapy can induce long-lasting immunity to SHIV.
Nishimura Y; Gautam R; Chun TW; Sadjadpour R; Foulds KE; Shingai M; Klein F; Gazumyan A; Golijanin J; Donaldson M; Donau OK; Plishka RJ; Buckler-White A; Seaman MS; Lifson JD; Koup RA; Fauci AS; Nussenzweig MC; Martin MA
Nature; 2017 Mar; 543(7646):559-563. PubMed ID: 28289286
[TBL] [Abstract][Full Text] [Related]
38. SIV-specific T lymphocyte responses in PBMC and lymphoid tissues of SIV-infected pigtailed macaques during suppressive combination antiretroviral therapy.
Carruth LM; Zink MC; Tarwater PM; Miller MD; Li M; Queen LA; Mankowski JL; Shen A; Siliciano RF; Clements JE
J Med Primatol; 2005 Jun; 34(3):109-21. PubMed ID: 15860119
[TBL] [Abstract][Full Text] [Related]
39. Initiation of antiretroviral therapy 48 hours after infection with simian immunodeficiency virus potently suppresses acute-phase viremia and blocks the massive loss of memory CD4+ T cells but fails to prevent disease.
Kubo M; Nishimura Y; Shingai M; Lee W; Brenchley J; Lafont B; Buckler-White A; Igarashi T; Martin MA
J Virol; 2009 Jul; 83(14):7099-108. PubMed ID: 19420078
[TBL] [Abstract][Full Text] [Related]
40. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA.
Van Rompay KK; Cherrington JM; Marthas ML; Lamy PD; Dailey PJ; Canfield DR; Tarara RP; Bischofberger N; Pedersen NC
Antimicrob Agents Chemother; 1999 Apr; 43(4):802-12. PubMed ID: 10103184
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
